Edesa Biotech ((EDSA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The JUST BREATHE study, officially titled Phase 2 Clinical Platform Trial Investigating Multiple Therapeutic Options for the Treatment of Hospitalized Patients With Acute Respiratory Distress Syndrome (ARDS), aims to evaluate the safety and efficacy of various host-directed therapies for ARDS. This significant trial seeks to improve treatment outcomes for hospitalized patients suffering from this critical condition.
The study tests three interventions: vilobelimab, paridiprubart, and bevacizumab, each administered intravenously. These treatments are designed to enhance patient recovery by targeting specific pathways involved in ARDS.
This Phase 2 trial employs a randomized, double-blinded, placebo-controlled design with a parallel intervention model. Participants are randomly assigned to receive either an active treatment or a placebo, with the primary aim of assessing treatment efficacy and safety.
The study began on June 10, 2025, with the most recent update submitted on July 10, 2025. These dates mark the trial’s progress and ensure transparency in its ongoing recruitment and data collection phases.
The update from Edesa Biotech could influence investor sentiment positively, as successful outcomes may enhance the company’s market position and stock performance. This study also positions Edesa among key industry players like Genentech and InflaRx, highlighting its competitive edge in ARDS treatment development.
The JUST BREATHE study is currently recruiting, with further details accessible on the ClinicalTrials portal.